

# **Emerging Issues in Vector-Borne Diseases: Arboviruses**


**Brian Byrd, PhD, MSPH  
Associate Professor  
College of Health and Human Sciences  
Western Carolina University**

# Arthropod Vectors




# Dengue and Chikungunya

- Epidemic Transmission
  - Human-Mosquito-Human
- Dengue: Flavivirus
- CHIKv: Alphavirus
- Peridomestic Transmission:
  - *Aedes* mosquitoes
    - *Aedes aegypti*
    - *Aedes albopictus*




# Dengue

- Dengue virus (DENV)
- Flavivirus
- Various closely related viruses
  - DENV1, DENV2, DENV3, DENV4
- Infection with 1 serotype gives type-specific protective immunity
- Subsequent infections with different serotypes increases risk for severe disease



# Dengue Virus


- Causes dengue and dengue hemorrhagic fever
- All serotypes can cause severe and fatal disease
- Genetic variation within serotypes
- Some genetic variants within each serotype appear to be more virulent or have greater epidemic potential



# Dengue Symptoms

- Dengue Fever: high fever, severe headache, severe pain behind the eyes, joint pain, muscle and bone pain, rash, and mild bleeding (e.g., nose or gums bleed, easy bruising).
- Severe Dengue (DHF/DSS): persistent vomiting, severe abdominal pain, internal bleeding, difficulty breathing, failure of the circulatory system and shock, followed by death

# Principle Vectors



*Aedes aegypti*

*Aedes albopictus*


Florida Medical Entomology Laboratory  
©1999 UNIVERSITY OF FLORIDA

# Reinfestation by *Aedes aegypti*

1930s



1970




1998






# Reported *Aedes aegypti* distribution (1986-2010)



Counties in the continental United States with collection records of *Ae. aegypti* from 1986 to 2010 (shaded red), based on information from a database for invasive mosquito species curated by C. G. Moore of Colorado State University. This database includes data from the Centers for Disease Control and Prevention ArboNet initiative, as well as reports from state and local public health and vector control programs, university researchers, and others.

# Reported and Predicted *Aedes albopictus* distribution



Predicted distribution maps and actual spread of *Ae. albopictus* in the lower 48 states. The predicted distribution areas (red) and the documented spread (yellow) of *Ae. albopictus* through the year 2001 are shown. One of the two prediction maps for the US is shown. Differences between the two consisted largely of one of the ten models used to create the prediction map that predicted a broader Texas distribution. Counties colored green are those in which introduction has occurred but not establishment.

# Main dengue vectors

## *Aedes aegypti*

- African treehole mosquito
- Closely associated with people
- Does not depend on the presence of vegetation
- Indoor / outdoor (resting, biting, ovipositing)
- Urban/suburban/rural areas
- Greater resistance to desiccation (eggs)
- Main dengue vector worldwide



## *Aedes albopictus*


- Asian treehole mosquito*
- Less dependent on people*
- Depends on tall vegetation*
- Outdoor mosquito*
- Suburban/rural areas*
- Main dengue vector in some areas / secondary*
- Greater cold hardiness*
- Better competitor in larval stage*



# Epidemiology


- Globally, most important arbovirus
- There are 390 million dengue infections per year, of which 96 million present some level of disease severity
- Mortality due to dengue can be  $<1\%$

# Global evidence consensus, risk and burden of dengue in 2010.



National and subnational evidence consensus on complete absence (green) through to complete presence (red) of dengue

# Global evidence consensus, risk and burden of dengue in 2010.



Cartogram of the annual number of infections for all ages as a proportion of national or subnational (China) geographical area

**nature**


# Dengue in the USA

- a. Endemic / epidemic dengue
  - i. *Aedes aegypti* is present: Puerto Rico, US Virgin Islands, and American Samoa
- b. Non-endemic – Risk for dengue emergence / re-emergence
  - i. *Aedes aegypti* / *Ae. albopictus* are present: Southern areas of Florida, Texas, Arizona, New Mexico, California
  - ii. *Aedes albopictus* is present: Guam, Mariana Islands, and Hawaii
- c. Non-endemic – Lower risk areas
  - i. *Aedes albopictus* is present: South Atlantic (Florida, Georgia, South Carolina, North Carolina, Virginia, West Virginia, Maryland, Delaware, Washington DC), Middle Atlantic (Pennsylvania, New Jersey, Connecticut, New York), East South Central (Mississippi, Alabama, Tennessee, Kentucky), West South Central (Louisiana, Oklahoma, Arkansas), and East North Central (Illinois, Indiana, Ohio)
- d. No dengue vectors - Risk for dengue vectors invasions but their establishment is unlikely
  - i. Pacific (Alaska, Washington, Oregon), Mountain (Montana, Idaho, Wyoming, Nevada, Utah, Colorado), West North Central (North Dakota, South Dakota, Minnesota, Nebraska, Iowa, Kansas, Missouri), and East North Central (Wisconsin, Michigan)

**In bold:** recent autochthonous dengue transmission

# Chikungunya Virus (CHIKV)

- Togoviridae, Alphavirus
- Infection likely provides life-long immunity
- Multiple virus strains with different epidemic potentials





# CHIKV

- Most infections are symptomatic (76-97%)
- Chikungunya virus infection can cause a debilitating illness, most often characterized by fever, headache, fatigue, nausea, vomiting, muscle pain, rash, and joint pain (similar to dengue)
- Chikungunya virus infection is thought to confer life-long immunity



# CHIKv


- Fatalities related to chikungunya virus are rare
- There is no vaccine or specific antiviral treatment currently available for chikungunya or dengue fever

**No Vaccine or Therapies:  
Prevention is the Key!**

# Rapid Spread in Caribbean

- Completely immunologically naïve population
- Social factors
- Environmental/ecological conditions
- Presence of both known epidemic vectors
- Insufficient/unavailable public health response
- High viremias/ long duration of viremia

# Assessing the Origin of and Potential for International Spread of Chikungunya Virus from the Caribbean




**States with Highest Average Temperature In May with Aedes Vector Reported**

State	Temperature °C
Puerto Rico	25.2
Florida	24.5
Louisiana	23.2
Texas	22.9
Mississippi	21.7
Georgia	21.4
South Carolina	21.1
Alabama	20.9
Arkansas	20.4
Oklahoma	20.2


## Traveler Volume

- 101 - 500
- 501 - 1,000
- 1,001 - 5,000
- > 5,000

Aedes aegypti or Aedes albopictus reported



States reporting chikungunya virus disease cases – United States, 2014  
*CDC*




States reporting chikungunya virus disease cases – United States, 2015  
(as of November 17, 2015)  
CDC

# **Emerging Issues in Vector-Borne Diseases: La Crosse Encephalitis**

**Brian Byrd, PhD, MSPH  
Associate Professor  
College of Health and Human Sciences  
Western Carolina University**

# La Crosse Virus (LACv)


- Isolated in 1960's in La Crosse, Wisconsin from a fatal case (4 y/o girl)
- Only acquired through the bite of a mosquito
  - Eastern-tree hole mosquito (principle vector)
- LACV is the most common arboviral cause of pediatric encephalitis in the US






Human Disease  
Mosquito-borne Pathogens (2004-2013): North Carolina

***La Crosse Encephalitis is the most common mosquito-borne disease in North Carolina***




# LACE (2003-2012)





Although LACE was historically found throughout the Midwest, burden has shifted to Appalachian region: 81% reported from Ohio, West Virginia, North Carolina, and Tennessee

(Gaensbauer et al., 2014)





Haddow AD and Odoi A, The incidence risk, clustering, and clinical presentation of La Crosse virus infections in the eastern United States, 2003-2007. *PLoS One*. 2009 Jul 3;4(7):e6145.



Western  
 Carolina  
 UNIVERSITY


# La Crosse Encephalitis

Illness is seen primarily in pediatrics






## Number of reported pediatric neuroinvasive arboviral disease cases due to La Crosse and West Nile viruses, by age at illness onset: United States, 2003–2012.




James T. Gaensbauer et al. *Pediatrics* 2014;134:e642-e650

# La Crosse Encephalitis Cases




\*Fatal Cases

# Annual Incidence per 100K (Western NC Counties)



**Pearson's  $r$  : -0.039**  
**95% CI: -0.21 – 0.14)**

# La Crosse Encephalitis Cases (NC: 1988-2011)






# “Tip of the Iceberg” Phenomenon



Tip of the Iceberg: 1 recognized LACE case

# “Tip of the Iceberg” Phenomenon



Iceberg: est. 100-300 individuals exposed to LACV

**Prevalence of La Crosse virus antibody in blood serum or Nobuto strip samples collected in western North Carolina\***



<b>Location</b>	<b>n</b>	<b>% positive per location</b>	<b>Overall % positive</b>
<b>Cherokee Indian Reservation</b>	<b>311</b>	<b>20.6</b>	<b>6.8</b>
<b>Macon County</b>	<b>36</b>	<b>8.3</b>	<b>0.3</b>
<b>Swain County</b>	<b>175</b>	<b>8.0</b>	<b>1.5</b>
<b>Jackson County</b>	<b>225</b>	<b>4.9</b>	<b>1.2</b>
<b>Haywood County</b>	<b>162</b>	<b>2.5</b>	<b>0.4</b>
<b>Eight additional counties</b>	<b>32</b>	<b>3.0</b>	<b>0.1</b>

\* The county of origin for 66 samples collected off the reservation was missing.

*Aedes triseriatus*



Photo Credit: CDC: J.Gathany (2002)



## La Crosse Virus Cycle

Adapted from Beaty and Marquardt (1996)

# INVASIVES: Secondary/Suspect Vectors

---



*Aedes albopictus*: Asian Tiger mosquito  
Competent in lab  
Found infected in nature



*Aedes japonicus*: Asian Bush mosquito  
Competent in lab  
Found infected in nature

MIR for *Ae. japonicus* (0.63) were lower than *Ae. triseriatus* (2.72) and *Ae. albopictus* (3.01) (Westby et al., 2015)

# Treeholes




# LACE Case Residence





# Peridomestic Artificial Containers Increase the abundance of *Aedes triseriatus*



# Prevention: Source Reduction

## ➤ Source Reduction

- “Tip and Toss” containers holding water
- Solid Waste Management
- Remember “cryptic” habitats
  - Check Rain Gutters
- Tree-hole Management



# Prevention: Personal

- Apply Repellents According to the Label
  - CDC Recommends EPA Registered Repellents\*
  - DEET, picaridin, IR3535, and some oil of lemon eucalyptus products
- Long Sleeves and Pants (As Appropriate)
- Avoid contact at “peak” hours



\*EPA registration means that EPA does not expect the product to cause adverse effects to human health or the environment when used according to the label.

# QUESTIONS?



**Brian D. Byrd, PhD, MSPH**  
**Western Carolina University**

**[bdbyrd@wcu.edu](mailto:bdbyrd@wcu.edu)**  
**<http://mosquito.wcu.edu>**



# Trapping Methods for LACv Vectors

- CDC light traps (baited)
  - Physiologically biased
  - Battery-powered
- BG-Sentinel
  - Physiologically biased
  - Battery-powered
- Nasci aspirator
  - Limitations: energy and time intensive strategy
- All have limited utility for surveillance & are ineffective for control



# CDC Autocidal Gravid Ovitrap

CDC-AGO:

Designed by the CDC for Dengue

Vector: *Ae. aegypti*

-Hay infusion: Microbial Cues

-Lure gravid females

-Affordable, low maintenance



# Study Aims (M. Henry)

- 1. Determine the efficacy of AGO for LACv vector surveillance
- 2. Compare attractiveness of a White Oak (WO) infusion versus hay infusion




# Abbreviated Methods

- AGOs (n=36) deployed in a balanced, randomized block design at 6 peridomestic sites for 5 weeks (630 trap days per infusion type)
- 6 traps (3 replicates per infusion type) per block
- Sites in LACE endemic area
- Mosquitoes removed 2X weekly






Block 1




Block 2



Block 3



Block 4



Block 5



Block 6

### Assign subjects to groups

Each column shows the assignments for a block. For example, the third column for the second row (not counting headings) shows the group assignment of the second subject of the third block.

Subject #	Block 1	Block 2	Block 3	Block 4	Block 5	Block 6
1	A	B	B	A	B	B
2	A	B	A	B	B	A
3	B	A	B	A	A	A
4	B	B	B	A	A	B
5	A	A	A	B	B	B
6	B	A	A	B	A	A

How it works: The random number generator is seeded with the time of day, so it works differently each time you use it. Each subject is first assigned to a group nonrandomly. Then the assignment of each subject is swapped with the group assignment of a randomly chosen subject. This should suffice, but the entire process is repeated twice to make sure it is really random. Note that you can copy and paste the values from the web page into Excel.

### Infusion Type

O = Oak

H = Hay



Distance between traps = 5 meters

# Methods

- Mosquitoes collected and processed
- Identified microscopically
- Physiological status determined (e.g., gravid)
- Unknowns -- Mol. techniques




*Ae. triseriatus* vs. *Ae. hendersoni* (Wilson et al., 2014)

# CDC-AGO highly specific for the three targeted LACv vectors (98.7%)


*Ae. triseriatus* (52.9%)  
*Ae. japonicus* (38.1%)  
*Ae. albopictus* (7.7%)

88% gravid



Mean yield of LACv vectors: **0.84** mosquitoes per trap per week  
Lower than yield observed in Dengue control (Barrera et al, 2014) efforts  
DEN AGO Study: Mean yield 1.2 mosquitoes per trap per week

# *Aedes triseriatus*\*




LANE	SAMPLE
A	100 bp ladder (DNA Standard)
B	<i>Ae. triseriatus</i> (691 bp) amplicon
C	<i>Ae. hendersoni</i> (550 bp) amplicon


Wilson R, Harrison R, Riles M, Wasserberg G, Byrd BD. Molecular identification of *Aedes triseriatus* and *Aedes hendersoni* by a novel duplex polymerase chain reaction assay. J Am Mosq Control Assoc. 2014 Jun;30(2):79-82.




# Species-Specific Mosquito Collections by Week



By Each Trap/ All Species  
(Overall Counts)




*Aedes triseriatus*  
(By Trap)



( $p < .05$ )

*Aedes japonicus*  
(by trap)



-Hay infusion more effective for trapping *Ae. triseriatus* than the oak leaf infusion ( $p < .05$ )

-Similar infusion study, similar results using gravid trap (Sither)

-Easier method

# Results/Significance:

- AGO collects targeted LACv vectors
- Results suggestive for future large-scale trials to reduce peridomestic LACv vector populations
- In this context, the AGOs may be useful as an environmental “sink”
- Ongoing studies to determine practicality of AGO
  - Does the AGO reduce proportion of gravid mosquitoes?
  - How does this influence disease risk?

# QUESTIONS?




**Brian D. Byrd, PhD, MSPH**  
**Western Carolina University**

**[bdbyrd@wcu.edu](mailto:bdbyrd@wcu.edu)**  
**<http://mosquito.wcu.edu>**









Adult Survivorship

Nuisance  
(Nulliparous)

Biting mosquitoes that have not previously taken a blood meal are a nuisance.

Blood feeding


Egg laying

Blood feeding

Vector  
(Parous)



Mosquitoes become vectors ready to transmit pathogens after laying eggs.

Mosquito Population Age







# Annual Incidence per 100K

LACE Incidence  
(per 100,000)



# Transmission Amplification Potential



**Hughes MT et al.** Comparative potential of *Aedes triseriatus*, *Aedes albopictus*, and *Aedes aegypti* (Diptera: Culicidae) to transovarially transmit La Crosse virus. J Med Entomol. 2006 Jul;43(4):757-61.

# Larval Indices

## ➤ House Index

$$HI = \frac{\text{\# of positive houses}}{\text{Total \# of houses surveyed}}$$

After effective control operations the HI=0

# Larval Indices

## ➤ Breteau Index

$$BI = \frac{\text{\# of positive containers}}{100 \text{ houses surveyed}}$$

Risk of dengue transmission when  $BI > 5$   
Emergency vector control when  $BI > 50$

# Larval Indices

## ➤ Container Index

$$CI = \frac{\text{\# of positive containers}}{\text{Total \# of containers survey}}$$

After effective control operations the CI=0

# Unknowns?

- Secondary Morphological Characters
- rDNA ITS2 size

